Enliven Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors aimed at treating cancer.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Stanley Druckenmiller / Duquesne | 81 | Added +105% | 947,405 | $19,393 | 0.5% |
| Andrew Law / Caxton | 64 | Holds (flat) | 13,097 | $268,106 | 1.2% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.